Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety
and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborators:
ADM Diagnostics, Inc. National Institute on Aging (NIA) Syneos Health University of Southern California